196 related articles for article (PubMed ID: 9818022)
21. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.
Berndt I; Reuter M; Saller B; Frank-Raue K; Groth P; Grussendorf M; Raue F; Ritter MM; Höppner W
J Clin Endocrinol Metab; 1998 Mar; 83(3):770-4. PubMed ID: 9506724
[TBL] [Abstract][Full Text] [Related]
22. RET protooncogene mutations in patients with apparently sporadic medullary thyroid carcinoma.
Huang CN; Wu SL; Chang TC; Huang SH; Chang TJ
J Formos Med Assoc; 1998 Aug; 97(8):541-6. PubMed ID: 9747064
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
Kambouris M; Jackson CE; Feldman GL
Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
[TBL] [Abstract][Full Text] [Related]
24. Mutations in the cysteine-rich region of the RET proto-oncogene in patients diagnosed as having sporadic medullary thyroid carcinoma.
Kimura T; Yoshimoto K; Yokogoshi Y; Saito S
Endocr J; 1995 Aug; 42(4):517-25. PubMed ID: 8556059
[TBL] [Abstract][Full Text] [Related]
25. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.
Hofstra RM; Landsvater RM; Ceccherini I; Stulp RP; Stelwagen T; Luo Y; Pasini B; Höppener JW; van Amstel HK; Romeo G
Nature; 1994 Jan; 367(6461):375-6. PubMed ID: 7906866
[TBL] [Abstract][Full Text] [Related]
26. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC.
Eng C; Smith DP; Mulligan LM; Healey CS; Zvelebil MJ; Stonehouse TJ; Ponder MA; Jackson CE; Waterfield MD; Ponder BA
Oncogene; 1995 Feb; 10(3):509-13. PubMed ID: 7845675
[TBL] [Abstract][Full Text] [Related]
27. Germline and somatic mutations of the RET proto-oncogene in apparently sporadic medullary thyroid carcinomas.
Scurini C; Quadro L; Fattoruso O; Verga U; Libroia A; Lupoli G; Cascone E; Marzano L; Paracchi S; Busnardo B; Girelli ME; Bellastella A; Colantuoni V
Mol Cell Endocrinol; 1998 Feb; 137(1):51-7. PubMed ID: 9607728
[TBL] [Abstract][Full Text] [Related]
28. Tumor-specific mutations in the tyrosine kinase domain of the RET proto-oncogene in pheochromocytomas of sporadic type.
Yoshimoto K; Tanaka C; Hamaguchi S; Kimura T; Iwahana H; Miyauchi A; Itakura M
Endocr J; 1995 Apr; 42(2):265-70. PubMed ID: 7627271
[TBL] [Abstract][Full Text] [Related]
29. [Somatic ret proto-oncogene mutations in sporadic C-cell carcinoma of the thyroid gland].
Frilling A; Bockhorn M; Kalinin V; Liedke M; Kaun M; Broelsch CE
Chirurg; 1997 Aug; 68(8):789-93. PubMed ID: 9377989
[TBL] [Abstract][Full Text] [Related]
30. [Ret proto-oncogene mutation found in the Czech population and its predictive value for offspring of patients with medullary carcinoma of the thyroid gland].
Mazura I; Vcelák J; Bendlová B; Neradilová M; Nĕmec J; Stolba P
Vnitr Lek; 1996 Nov; 42(11):751-6. PubMed ID: 9012117
[TBL] [Abstract][Full Text] [Related]
31. [Molecular diagnosis of multiple type 2 endocrine neoplasia].
Amosenko FA; Pushkash K; Frilling A; Kozlova VN; Liubchenko LN; Kazubskaia TP; Brelysh KE; Gar'kavtseva RF; Kalinin VN
Vestn Ross Akad Med Nauk; 2001; (2):34-7. PubMed ID: 11338505
[TBL] [Abstract][Full Text] [Related]
32. Germ line mutations of the ret proto-oncogene in Japanese patients with multiple endocrine neoplasia type 2A and type 2B.
Maruyama S; Iwashita T; Imai T; Funahashi H; Ceccherini I; Luo Y; Romeo G; Matsuo S; Matsuyama M; Takahashi M
Jpn J Cancer Res; 1994 Sep; 85(9):879-82. PubMed ID: 7961113
[TBL] [Abstract][Full Text] [Related]
33. A complex nine base pair deletion in RET exon 11 common in sporadic medullary thyroid carcinoma.
Alemi M; Lucas SD; Sällström JF; Bergholm U; Akerström G; Wilander E
Oncogene; 1997 May; 14(17):2041-5. PubMed ID: 9160884
[TBL] [Abstract][Full Text] [Related]
34. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma.
Eng C; Mulligan LM; Healey CS; Houghton C; Frilling A; Raue F; Thomas GA; Ponder BA
Cancer Res; 1996 May; 56(9):2167-70. PubMed ID: 8616867
[TBL] [Abstract][Full Text] [Related]
35. Absence of mutations at codon 768 of the RET proto-oncogene in sporadic and hereditary pheochromocytomas.
Yoshimoto K; Kimura T; Tanaka C; Moritani M; Iwahana H; Itakura M
Endocr J; 1996 Feb; 43(1):109-14. PubMed ID: 8732460
[TBL] [Abstract][Full Text] [Related]
36. Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation.
Gimm O; Neuberg DS; Marsh DJ; Dahia PL; Hoang-Vu C; Raue F; Hinze R; Dralle H; Eng C
Oncogene; 1999 Feb; 18(6):1369-73. PubMed ID: 10022819
[TBL] [Abstract][Full Text] [Related]
37. Mutation of the RET proto-oncogene is correlated with RET immunostaining in subpopulations of cells in sporadic medullary thyroid carcinoma.
Eng C; Thomas GA; Neuberg DS; Mulligan LM; Healey CS; Houghton C; Frilling A; Raue F; Williams ED; Ponder BA
J Clin Endocrinol Metab; 1998 Dec; 83(12):4310-3. PubMed ID: 9851769
[TBL] [Abstract][Full Text] [Related]
38. Medullary thyroid carcinoma: recent advances and management update.
Marsh DJ; Learoyd DL; Robinson BG
Thyroid; 1995 Oct; 5(5):407-24. PubMed ID: 8563482
[TBL] [Abstract][Full Text] [Related]
39. RET proto-oncogene point mutations in sporadic neuroendocrine tumors.
Komminoth P; Roth J; Muletta-Feurer S; Saremaslani P; Seelentag WK; Heitz PU
J Clin Endocrinol Metab; 1996 Jun; 81(6):2041-6. PubMed ID: 8964826
[TBL] [Abstract][Full Text] [Related]
40. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
Sansó G; Domené HM; Iorcansky S; Barontini M
Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
